Effects of I-125 seeds combined with anlotinib on tumor growth and bone metabolism in A549 tumor-bearing mice

References

• Ankem MK, DeCarvalho VS, Harangozo AM, Hartanto VH, Perrotti M, Han K, Shih WJ, Malka E, White EC, Maggio R, et al. 2002. Implications of radioactive seed migration to the lungs after prostate brachytherapy. Urology. 59(4):555–559.
   PubMed Web of Science ®Google Scholar
• Baudino TA. 2015. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 12(1):3–20.
   PubMedGoogle Scholar
• Bledsoe TJ, Nath SK, Decker RH. 2017. Radiation pneumonitis. Clin Chest Med. 38(2):201–208.
   PubMed Web of Science ®Google Scholar
• Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, Aapro M, Coleman R. 2016. Bone health in the elderly cancer patient: a SIOG position paper. Cancer Treat Rev. 51:46–53.
   PubMed Web of Science ®Google Scholar
• Cooper MR, Binkowski C, Hartung J, Towle J. 2016. Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer. Onco Targets Ther. 9:1953–1960.
   PubMed Web of Science ®Google Scholar
• D'Oronzo S, Stucci S, Tucci M, Silvestris F. 2015. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev. 41(9):798–808.
   PubMed Web of Science ®Google Scholar
• Handforth C, D'Oronzo S, Coleman R, Brown J. 2018. Cancer treatment and bone health. Calcif Tissue Int. 102(2):251–264.
   PubMed Web of Science ®Google Scholar
• Jiang YL, Meng N, Wang JJ, Ran WQ, Yuan HS, Qu A, Yang RJ. 2010. Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck. Cancer Biol Ther. 9(12):959–966.
   PubMed Web of Science ®Google Scholar
• Keating GM. 2014. Bevacizumab: a review of its use in advanced cancer. Drugs. 74(16):1891–1925.
   PubMed Web of Science ®Google Scholar
• Lee YT, Tan YJ, Oon CE. 2018. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 834:188–196.
   PubMed Web of Science ®Google Scholar
• Li W, Dan G, Jiang J, Yang L, Huang X. 2010. Skills and the clinical application of CT guided radioactive seed 125I implantation in treating multiple lung metastatic masses. Zhongguo Fei Ai Za Zhi. 13(3):230–233.
   PubMedGoogle Scholar
• Li W, Guan J, Yang L, Zheng X, Yu Y, Jiang J. 2015. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III/IV non-small cell lung cancer versus the conventional radiotherapy. Med Oncol. 32(1):395.
   PubMed Web of Science ®Google Scholar
• Li W, Wang X, Wang Z, Zhang T, Cai F, Tang P, Meng J, Du H, Wang H, Li M, et al. 2020. The role of seed implantation in patients with unresectable pancreatic carcinoma after relief of obstructive jaundice using ERCP. Brachytherapy. 19(1):97–103.
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. 2018. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 654:77–86.
   PubMed Web of Science ®Google Scholar
• Park DS, Gong IH, Choi DK, Hwang JH, Shin HS, Oh JJ. 2013. Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: a matched cohort analysis. World J Urol. 31(6):1511–1517.
   PubMed Web of Science ®Google Scholar
• Qu A, Wang H, Li J, Wang J, Liu J, Hou Y, Huang L, Zhao Y. 2014. Biological effects of (125)i seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest. 32(6):209–217.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, et al. 2014. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 120(8):1145–1154.
   PubMed Web of Science ®Google Scholar
• Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, Li K, Wang Q, Shi J, Wang Z, et al. 2019. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac Cancer. 10(3):551–556.
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, et al. 2016. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 9(1):105.
   PubMedGoogle Scholar
• Takahashi S. 2011. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 34(12):1785–1788.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Yu H, et al. 2018. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment. Cancer Biol Med. 15(4):443–451.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang X, Guan Y, Song Y, Zhuang H, Wang E. 2020. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol. Thorac Cancer. 11(5):1361–1364.
   PubMed Web of Science ®Google Scholar
• Wang ZM, Lu J, Liu T, Chen KM, Huang G, Liu FJ. 2011. CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer. Lung Cancer. 74(2):253–257.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. 2014. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15(11):1224–1235.
   PubMed Web of Science ®Google Scholar
• Willey JS, Lloyd SA, Nelson GA, Bateman TA. 2011. Ionizing radiation and bone loss: space exploration and clinical therapy applications. Clin Rev Bone Miner Metab. 9(1):54–62.
   PubMedGoogle Scholar
• Xiang GL, Zhu XH, Lin CZ, Wang LJ, Sun Y, Cao YW, Wang FF. 2017. 125I seed irradiation induces apoptosis and inhibits angiogenesis by decreasing HIF-1α and VEGF expression in lung carcinoma xenografts. Oncol Rep. 37(5):3075–3083.
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. 2018. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 109(4):1207–1219.
   PubMed Web of Science ®Google Scholar
• Yan WL, Lv JS, Guan ZY, Wang LY, Yang JK, Liang JX. 2017. Impact of target area selection in (125) iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer. Thorac Cancer. 8(3):147–152.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Z, Wang Q. 2019. Emerging therapies for small cell lung cancer. J Hematol Oncol. 12(1):47.
   PubMedGoogle Scholar
• Yu X, Li J, Zhong X, He J. 2015. Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy. BMC Cancer. 15:656.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang J, Guo J, Li Y, Huang X, Guan Z, Lei G, Wang J, Ye X, Zhao X, et al. 2019. Chinese Expert Consensus Workshop Report: guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors. Thorac Cancer. 10(2):388–394.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, et al. 2019. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun. 39(1):36.
   Google Scholar